For Adult Patients With Moderately to Severely Active CD

*In both the CD and UC studies, many patients achieved clinical remission at 1 year with STELARA®.

Rapid Response1

Many patients achieved clinical response at Week 6 and 70-point response as early as Week 3 in clinical studies

Lasting Remission2

Many patients achieved clinical remission at 1 year in a clinical study

Safety Profile1

The overall safety profile of STELARA® at 1 year in CD was consistent with that seen in other approved indications

Resources to help your patients

Local Coverage

Commercial Formulary Coverage Look-up

Enter Your ZIP Code to View Coverage Results

Please enter zip code  

All information is subject to change. Actual benefits determined by health plan. We strongly recommend you call the health plan for its reimbursement policies. This information does not advise on or guarantee coverage or payment.

STELARA withMe is here to support your patients

STELARA withMe provides a range of dedicated support and resources to help make it easier for patients as they begin, and continue, their STELARA® treatment journey.

The Provider Portal is still available. There you can request and review benefits investigations, enroll eligible patients in the STELARA withMe Savings Program, and view Savings Program transactions as requested by the patient.

CD=Crohn's disease; UC=ulcerative colitis.


References: 1. STELARA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Data on file. Janssen Biotech, Inc.